Compare Biogen Inc (BIIB) vs Mercadolibre Inc (MELI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Biogen Inc vs Mercadolibre Inc — how do they compare? Biogen Inc trades at $190.6 (market cap $28.34B), while Mercadolibre Inc trades at $1,854.37 (market cap $95.00B). The key difference: Mercadolibre Inc is far larger — about 3.4× Biogen Inc's market cap, and Mercadolibre Inc is trading nearer its 52-week high, Biogen Inc nearer its low. Which is the better fit depends on your goals.
| BIIB | MELI | |
|---|---|---|
Market Cap | $28.34B | $95.00B |
Sector | Health | Consumer Cyclical |
52-Week High | $216.63 | $2.51K |
52-Week Low | $122.68 | $1.55K |
Enterprise Value | $30.62B | $101.89B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Biogen (BIIB) trades at $209.03, up 4.96% today, with a bullish technical signal and strong analyst support. Recent quarterly earnings have consistently beaten expectations, and the company maintains solid profitability with a 75.49% gross margin. Key developments include FDA approval for a subcutaneous starter dose of Leqembi and promising Phase 2 data for its Alzheimer's drug diranersen, driving positive sentiment.
The outlook is positive, with a consensus price target of $230.18 suggesting upside. Investment opportunities lie in Alzheimer's pipeline advancements, but risks include clinical trial outcomes and competitive pressures. Revenue stability and cost management support fundamentals, though regulatory hurdles remain a watchpoint.
MercadoLibre (MELI) trades at $1,867.30, up 0.81% today, with a bullish technical signal and strong analyst support. Recent financials show robust revenue growth to $28.89 billion in 2025, though net income margins compressed to 6.04%. The stock faces near-term pressure from three consecutive quarterly EPS misses but benefits from expanding cash flow and a dominant position in Latin American e-commerce and fintech.
Outlook remains positive with a consensus price target of $2,230, implying 19% upside, but risks include margin volatility from heavy investments and competitive threats. Institutional sentiment is strong with 72% buy ratings, though high P/E of 49.28 demands sustained growth to justify valuation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Biogen Inc
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel MS drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogen's MS portfolio is co-promoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with SOBI) were spun off as part of Bioverativ in 2017. Biogen has several drug candidates in phase 3 trials in neurology and neurodegenerative diseases and has launched Spinraza with partner Ionis. Aduhelm was approved as the firm's first Alzheimer's disease therapy in June 2021.
Read more on BIIB →About Mercadolibre Inc
MercadoLibre runs the largest e-commerce marketplace in Latin America, connecting a network of more than 140 million active users and 1 million active sellers as of the end of 2021 across an 18-country footprint. The company also operates a host of complementary businesses, with shipping solutions (Mercado Envios), a payment and financing operation (Mercado Pago), advertisements (Mercado Clics), classifieds, and a turnkey e-commerce solution (Mercado Shops) rounding out its arsenal. MercadoLibre generates revenue from final value fees, advertising royalties, payment processing, insertion fees, subscription fees, and interest income from consumer and small-business lending.
Read more on MELI →
